Repligen company profile

RGEN · NASDAQ · USD

Compare Repligen
$165.39Change from previous close: −1.43%Absolute change: −$2.40

Close · November 16, 2026

Company profile

Repligen has 2,000 employees and is headquartered in Waltham, United States.

Biologic drug makers, contract manufacturers, diagnostic firms and bench-level researchers make up the customer base of Repligen Corporation, which develops bioprocessing technologies and systems in North America, Europe and the Asia Pacific region. Its offering spans filtration units such as cell retention systems and tangential flow cassettes, chromatography columns used to purify biological drugs, Protein A ligands, cell culture growth factors, ELISA kits, and process analytics instruments that monitor critical production parameters in real time. Products are sold under brands including OPUS, XCell, KrosFlo and SoloVPE. A collaboration agreement with Navigo Proteins GmbH covers the development of several affinity ligands.

In the fiscal year ended December 2025, Repligen reported revenue of 738.3 million US dollars, up 16.4% from the previous year, and net income of 48.9 million US dollars. The company had 2,000 employees. It was incorporated in 1981 and has its headquarters in Waltham, Massachusetts.

Company facts

Industry
Medical Instruments & Supplies
Headquarters
Building 1, 02453, Waltham
Employees
2,000
Chief executive
Olivier Loeillot
Founded
1981
Fiscal year
January - December
Listing
RGEN · NASDAQ
Currency
USD
ISIN
US7599161095

Repligen and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
RepligenRGENUnited States$10.73B2,0008.1%—
AvantorAVTRUnited States$10.46B13,5008.0%30.9
Align TechnologyALGNUnited States$11.86B20,18019.6%24.5
Cooper CompaniesCOOUnited States$11.91B15,00012.9%21.5
AptarGroupATRUnited States$9.12B14,00012.4%34.4
Baxter InternationalBAXUnited States$13.39B37,5007.6%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Repligen with its competitors